循环可溶性 CD163 作为糖尿病并发症的潜在生物标志物。
Circulating soluble CD163 as a potential biomarker of diabetes complications.
机构信息
Greg Brown Diabetes and Endocrine Research Laboratory, Sydney Medical School (Central), Faculty of Medicine and Health, Charles Perkin Centre, The University of Sydney, Sydney, NSW, Australia.
Greg Brown Diabetes and Endocrine Research Laboratory, Sydney Medical School (Central), Faculty of Medicine and Health, Charles Perkin Centre, The University of Sydney, Sydney, NSW, Australia; Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
出版信息
J Diabetes Complications. 2023 Aug;37(8):108525. doi: 10.1016/j.jdiacomp.2023.108525. Epub 2023 Jun 5.
AIMS
To investigate whether soluble CD163 (sCD163) is altered in those with diabetes and various subtypes of complications and non-alcoholic fatty liver disease (NAFLD), and whether it can assess disease complications and severity in people with diabetes.
METHODS
Adults with diabetes (n = 101) were recruited and assessed for the presence of any complications (D). Liver steatosis presence was determined by ultrasound and liver stiffness measurement (LSM) by transient elastography. Liver pathology other than non-alcoholic steatohepatitis (NASH) was excluded. Plasma sCD163 was measured by ELISA.
RESULTS
sCD163 was higher in D (n = 59) compared to D (n = 42) in those with microvascular complications (n = 56; 1.3-fold), including a 1.4-fold increase in chronic kidney disease (CKD) (n = 42). sCD163 correlated positively with HbA and urinary albumin-creatinine ratio and negatively with HDL-c in D. sCD163 was increased 1.7-fold in those with advanced NASH fibrosis (LSM ≥ 10.3 kPa, n = 19) compared to those without (LSM < 10.3 kPa, n = 80). The AUC-ROC-curve was 0.64 for sCD163 to detect CKD and 0.74 to detect advanced NASH fibrosis.
CONCLUSIONS
In this study, the elevated circulating sCD163 occurred in people with diabetes who had microvascular complications or advanced NASH fibrosis, suggesting sCD163 may have clinical utility as a biomarker in certain diabetes complications and disease severity in NAFLD.
目的
研究可溶性 CD163（sCD163）在糖尿病患者及其各种并发症和非酒精性脂肪性肝病（NAFLD）亚型中的变化情况，以及其是否可用于评估糖尿病患者的疾病并发症和严重程度。
方法
招募了患有糖尿病的成年人（n=101），并评估其是否存在任何并发症（D）。通过超声和瞬时弹性成像测量肝硬度（LSM）来确定肝脂肪变性的存在。排除非酒精性脂肪性肝炎（NASH）以外的肝病理学改变。通过 ELISA 法测量血浆 sCD163。
结果
在有微血管并发症（n=56；1.3 倍）的 D 组（n=59）中，sCD163 高于 D 组（n=42），包括慢性肾脏病（CKD）（n=42）增加 1.4 倍。sCD163 与 HbA 和尿白蛋白/肌酐比值呈正相关，与 HDL-c 呈负相关。与无晚期 NASH 纤维化（LSM≥10.3kPa，n=19）的患者相比，sCD163 在 LSM≥10.3kPa 的患者中增加了 1.7 倍（LSM<10.3kPa，n=80）。sCD163 检测 CKD 的 AUC-ROC 曲线下面积为 0.64，检测晚期 NASH 纤维化的 AUC-ROC 曲线下面积为 0.74。
结论
在这项研究中，患有微血管并发症或晚期 NASH 纤维化的糖尿病患者循环 sCD163 升高，表明 sCD163 可能作为一种生物标志物在某些糖尿病并发症和 NAFLD 疾病严重程度方面具有临床应用价值。
Zotero 插件